The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Phase II Study of an Omega-3 Fatty Acid in TNBC Survivors

Neil M. Iyengar, MD
Published Online: 5:48 PM, Thu December 12, 2013
Neil M. Iyengar, MD, Fellow, Medical Oncology and Hematology, Breast Medicine Service, Memorial Sloan-Kettering Cancer Center, discusses a phase II study looking at an omega-3 fatty acid in triple-negative breast cancer (TNBC) survivors.

Clinical Pearls

  • This phase II study looks to analyze whether DHA, an omega-3 fatty acid, will reduce circulating markers of inflammation in overweight/obese patients with a history of TNBC
  • In another poster, it was hypothesized that targeting the inflammation-aromatase axis with an omega-3 fatty acid could decrease the risk for relapse or development of breast cancer
  • This trial will look at breast tissue pre- and post-intervention to determine if there is a decreases in inflammatory markers after 3 months of treatment with the omega-3 fatty acid

<<< Back to the conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.